Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Julius

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten|January 1, 1985
[Results of protein-sparing modified fasting in hyperlipoproteinemias]S Fischer, M Hanefeld, M Weck, et al.
Atherosclerosis. Supplements|May 5, 2015
Effects of lipoprotein apheresis on PCSK9 levelsU Julius, M Milton, D Stoellner, et al.
Human Mutation|January 4, 2001
Eight novel LDL receptor gene mutations among patients under LDL apheresis in Dresden and LeipzigH Bochmann, J Geisel, W Herrmann, et al.
Atherosclerosis. Supplements|November 4, 2017
Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years onV J J Schettler, C L Neumann, C Peter, et al.
Atherosclerosis. Supplements|January 30, 2013
Differential effects of lipoprotein apheresis by lipidfiltration or dextran sulfate adsorption on lipidomic profileJ Gräßler, S Kopprasch, J Passauer, et al.
Journal of Clinical Lipidology|June 21, 2018
Treatment-related and health-related quality of life in lipoprotein apheresis patientsV De Gucht, K Cromm, A Vogt, et al.
Clinical Research in Cardiology Supplements|July 19, 2017
Erratum to: The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years onV J J Schettler, C L Neumann, C Peter, et al.
Atherosclerosis. Supplements|May 5, 2015
First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemiasC Stefanutti, G D'Alessandri, A Petta, et al.
Clinical Research in Cardiology Supplements|February 25, 2017
The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years onV J J Schettler, C L Neumann, C Peter, et al.
Clinical Research in Cardiology Supplements|March 7, 2019
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levelsV J J Schettler, C L Neumann, C Peter, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten|January 1, 1985
[Results of protein-sparing modified fasting in hyperlipoproteinemias]S Fischer, M Hanefeld, M Weck, et al.
Atherosclerosis. Supplements|May 5, 2015
Effects of lipoprotein apheresis on PCSK9 levelsU Julius, M Milton, D Stoellner, et al.
Human Mutation|January 4, 2001
Eight novel LDL receptor gene mutations among patients under LDL apheresis in Dresden and LeipzigH Bochmann, J Geisel, W Herrmann, et al.
Atherosclerosis. Supplements|November 4, 2017
Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years onV J J Schettler, C L Neumann, C Peter, et al.
Atherosclerosis. Supplements|January 30, 2013
Differential effects of lipoprotein apheresis by lipidfiltration or dextran sulfate adsorption on lipidomic profileJ Gräßler, S Kopprasch, J Passauer, et al.
Journal of Clinical Lipidology|June 21, 2018
Treatment-related and health-related quality of life in lipoprotein apheresis patientsV De Gucht, K Cromm, A Vogt, et al.
Clinical Research in Cardiology Supplements|July 19, 2017
Erratum to: The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years onV J J Schettler, C L Neumann, C Peter, et al.
Atherosclerosis. Supplements|May 5, 2015
First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemiasC Stefanutti, G D'Alessandri, A Petta, et al.
Clinical Research in Cardiology Supplements|February 25, 2017
The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years onV J J Schettler, C L Neumann, C Peter, et al.
Clinical Research in Cardiology Supplements|March 7, 2019
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levelsV J J Schettler, C L Neumann, C Peter, et al.
Pageof 12